Abstract
Dopamine oxidation is proposed to be a significant contributor to mesostriatal dopaminergic neurodegeneration, although the mechanisms are not fully resolved. Recent results from in vitro and in vivo models have suggested that some products from mercapturic acid pathway (MAP) metabolism of oxidized dopamine (DA) may contribute to dopaminergic neurodegeneration, and that at least one product of this pathway, 5-S-cysteinyldopamine (Cys-DA), is elevated in patients with advanced Parkinsons disease (PD). Here we review recent findings on MAP enzymes and their products in rodent brain and in diseased regions of brain from patients with mesostriatal dopaminergic neurodegeneration. We also review the current data and our recent findings on the neurobiological activity of MAP metabolites of oxidized DA. We conclude that human striatum has limited enzymatic capacity for mercapturate formation, that levels of MAP products of oxidized DA are significantly elevated in PD patients with advanced dopaminergic neurodegeneration but not in patients with less severe degeneration, and that Cys-DA interferes with trafficking of DA in vitro and in vivo. These results indicate that Cys-DA may interfere with DA trafficking in patients with advanced dopaminergic neurodegeneration.
Current Topics in Medicinal Chemistry
Title: Dopamine Thioethers in Neurodegeneration
Volume: 1 Issue: 6
Author(s): Kathrin R. Sidell, Ventkataraman Amarnath and Thomas J. Montine
Affiliation:
Abstract: Dopamine oxidation is proposed to be a significant contributor to mesostriatal dopaminergic neurodegeneration, although the mechanisms are not fully resolved. Recent results from in vitro and in vivo models have suggested that some products from mercapturic acid pathway (MAP) metabolism of oxidized dopamine (DA) may contribute to dopaminergic neurodegeneration, and that at least one product of this pathway, 5-S-cysteinyldopamine (Cys-DA), is elevated in patients with advanced Parkinsons disease (PD). Here we review recent findings on MAP enzymes and their products in rodent brain and in diseased regions of brain from patients with mesostriatal dopaminergic neurodegeneration. We also review the current data and our recent findings on the neurobiological activity of MAP metabolites of oxidized DA. We conclude that human striatum has limited enzymatic capacity for mercapturate formation, that levels of MAP products of oxidized DA are significantly elevated in PD patients with advanced dopaminergic neurodegeneration but not in patients with less severe degeneration, and that Cys-DA interferes with trafficking of DA in vitro and in vivo. These results indicate that Cys-DA may interfere with DA trafficking in patients with advanced dopaminergic neurodegeneration.
Export Options
About this article
Cite this article as:
Kathrin R. Sidell , Ventkataraman Amarnath and Thomas J. Montine , Dopamine Thioethers in Neurodegeneration, Current Topics in Medicinal Chemistry 2001; 1 (6) . https://dx.doi.org/10.2174/1568026013394705
DOI https://dx.doi.org/10.2174/1568026013394705 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Medicinal Chemistry Advancement in Life-Threatening Diseases
The current issue will highlight concise reports that specify ground-breaking insights, including the novel discovery of drug targets and their action mechanism or drugs of novel classes. These are projected to encourage medicinal chemistry future efforts to address the most challenging medical needs. The current issue highlights further efforts to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
In-hospital Falls in Older Patients: The Risk Factors and The Role of Hyponatraemia
Current Aging Science Non-invasive Cerebellar Stimulation in Cerebellar Disorders
CNS & Neurological Disorders - Drug Targets Effect of Synthetic Cannabinoid HU210 on Memory Deficits and Neuropathology in Alzheimers Disease Mouse Model
Current Alzheimer Research Nanostructured Lipid Carrier Containing CNS Acting Drug: Formulation, Optimization and Evaluation
Current Nanoscience Multi-Faceted Aspects ofGamma-Hydroxybutyric Acid: A Neurotransmitter, Therapeutic Agent and Drug of Abuse
Mini-Reviews in Medicinal Chemistry Cholesterol and LDL Relate to Neuritic Plaques and to APOE4 Presence but Not to Neurofibrillary Tangles
Current Alzheimer Research The Response of the Aged Brain to Stroke: Too Much, Too Soon?
Current Neurovascular Research Serotonin 5-HT6 Receptor Antagonists for the Treatment of Alzheimers Disease
Current Topics in Medicinal Chemistry Non-Steroidal LXR Agonists; An Emerging Therapeutic Strategy for the Treatment of Atherosclerosis
Recent Patents on Cardiovascular Drug Discovery PCSK9 Inhibitors for the Management of Dyslipidemia in People with Type 2 Diabetes: How Low is Too Low?
Current Pharmaceutical Design The Role of Lipids and Membranes in the Pathogenesis of Alzheimer's Disease: A Comprehensive View
Current Alzheimer Research β -Amyloid: A Disease Target or a Synaptic Regulator Affecting Age-Related Neurotransmitter Changes?
Current Pharmaceutical Design 4-Acetamidobenzaldehyde Derivatives as Biological Active Candidates; Synthesis, Anti-oxidant, Anti-Alzheimer and DNA Binding Studies
Letters in Drug Design & Discovery Electrochemical Biosensors for the Determination of the Antioxidant Capacity in Foods and Beverages Based on Reactive Oxygen Species
Current Analytical Chemistry Risk Stratification for Sudden Cardiac Death: Current Approaches and Predictive Value
Current Cardiology Reviews Bromazepam Impairs Motor Response: An ERSP Study
CNS & Neurological Disorders - Drug Targets Comparison of Changes in Cognitive Functions of Post-stroke Patients with the Computer-based Cognitive Intervention (PABLO System) and Conventional Cognitive Intervention (Paper-pencil Method)
Current Psychiatry Research and Reviews Gene Therapy in the Transplantation of Allogeneic Organs and Stem Cells
Current Gene Therapy Carbohydrate-Based Bioactive Compounds for Medicinal Chemistry Applications
Mini-Reviews in Medicinal Chemistry Brain MRI, Apoliprotein E Genotype, and Plasma Homocysteine in American Indian Alzheimer Disease Patients and Indian Controls
Current Alzheimer Research